



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/209383/>

Version: Published Version

Article:

Ball, A.J., Aziz, I., Sargur, R.B. et al. (2024) Rejection of fecal immunochemical tests within the lower gastrointestinal diagnostic pathway: a cohort study. *Journal of Primary Care & Community Health*, 15. ISSN: 2150-1319

<https://doi.org/10.1177/21501319241228161>

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial (CC BY-NC) licence. This licence allows you to remix, tweak, and build upon this work non-commercially, and any new works must also acknowledge the authors and be non-commercial. You don't have to license any derivative works on the same terms. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Rejection of Fecal Immunochemical Tests Within the Lower Gastrointestinal Diagnostic Pathway: A Cohort Study

Journal of Primary Care & Community Health
Volume 15: 1–6
© The Author(s) 2024
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/21501319241228161
journals.sagepub.com/home/jpc



Alex J. Ball¹, Imran Aziz^{1,2}, Ravishankar B. Sargur³, Louise Merriman⁴, and Matthew Kurien^{1,2} 

Abstract

Introduction/Objectives: The fecal immunochemical test (FIT) helps triage primary care patients at risk of colorectal cancer (CRC). Improving FIT returns has received recent attention, however uncertainty exists regarding the accurate completion of samples provided for laboratory analysis. This study aims to identify the rejection rate of returned FIT samples and determine rejection causes. **Methods:** FIT samples from symptomatic patients within South Yorkshire, Bassetlaw, and North Derbyshire are processed at a central laboratory. Tests requests are made from 225 GP practices, which serve an estimated 2 million population. This study describes a retrospective review of FIT samples received in the central laboratory between 01/09/19 and 31/12/22. Locally held data was interrogated in March 2023 to determine the number of FIT samples received and rejected during the study period. Documented reasons for rejection were explored to identify common themes. **Results:** Total FIT specimens received during the study period was 126 422. Of these, 5190 (4.1%) were rejected. Monthly rejection rates fell from 17.4% in September 2019 to 1.3% in December 2022 ($P < .001$). Sampling errors were the most frequent cause for FIT rejection (2151/5190), with other causes including: expired specimen; no sample collection date/ time, no request form, incomplete patient information and illegible handwriting. **Conclusions:** This is the first study exploring FIT rejection rates in symptomatic primary care patients, which shows improvements in rejection rates over time. Targeted interventions could improve rejection rates further, thereby reducing NHS resource use and costs and diagnostic delays.

Keywords

fecal immunochemical test, colorectal cancer, rejected specimen, diagnostic delays

Dates received: 2 October 2023; revised: 3 January 2024; accepted: 5 January 2024.

Introduction

Colorectal cancer (CRC) is the fourth most common cancer in the UK. It is the second leading cause of cancer related deaths, with 16 800 deaths occurring annually.¹ An expedited diagnosis is recognized to improve survival for many cancers, with this evidence being strongest in bowel cancer.^{1–3} Currently, only 39.4% of UK patients with bowel cancer are detected at the earliest stages (stage 1 or stage 2). This influences the likelihood of receiving curative therapies, with symptomatic individuals more likely to present with more advanced disease. Recent research has demonstrated that a 2-month diagnostic delay in CRC is associated with a >9% reduction in 10-year survival.⁴ This emphasizes the importance in minimizing any diagnostic delays existing within the lower gastrointestinal diagnostic pathway.

The fecal immunochemical test (FIT) is now embedded within the 2-week wait (2WW) lower gastrointestinal (LGI) diagnostic pathway in England.⁵ Its recognized advantages

¹Department of Gastroenterology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, UK

²Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Sheffield, South Yorkshire, UK

³Department of Allergy and Immunology, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, South Yorkshire, UK

⁴Springs Health Centre, Chesterfield, Derbyshire, UK

Corresponding Author:

Matthew Kurien, Division of Clinical Medicine, School of Medicine & Population Health, University of Sheffield, Beech Hill Road, Sheffield, South Yorkshire S10 2RX, UK.

Email: m.kurien@sheffield.ac.uk



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons

Attribution-NonCommercial 4.0 License (<https://creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

over symptoms in predicting CRC has seen FIT evolve from a diagnostic test to a key adjunct in triaging of referrals and the prioritization of investigations, which remain compromised following the COVID-19 pandemic.⁶⁻⁸ Despite the increased adoption of FIT testing in symptomatic services, which involves patients completing samples at home, challenges persist in ensuring timely and consistent test returns.^{9,10} This is particularly problematic in under-served populations.¹¹⁻¹³

There is very limited work currently looking at the accurate completion of FIT specimens, which are returned to laboratories for processing. This largely unmeasured aspect of the lower gastrointestinal diagnostic pathway impacts its efficiency, as rejection rates may influence diagnostic delays, lead to potential test abandonment, and negatively influence NHS resource use and costs. In 2 bowel cancer screening studies from the USA (asymptomatic populations), the FIT specimen rejection rate ranged between 17% and 42%.^{14,15} Our previous study examining FIT outcomes in a low-risk symptom population identified a 14.2% FIT rejection rate over a 3 month period (Oct-Dec 2019).¹⁶ This incidental and potentially concerning finding led to this real-world study, which explores FIT rejection rates over a more prolonged period of time and determines why submitted samples were rejected.

Methods

Design and Setting

There are 225 primary care practices in South Yorkshire, Bassetlaw, and North Derbyshire, UK. These 225 practices serve an estimated population of 2 million people, with adult secondary care (including endoscopy services) provided by 8 hospitals. FIT has been used locally within these primary care practices since January 2018. This use of FIT followed National Institute for Health and Care Excellence Diagnostic Guidelines 30 (NICE DG30), which recommended the FIT to guide referral of patients with low-risk symptoms of CRC within primary care.⁵ Patients eligible for FIT was extended in March 2021 following a NICE publication in November 2020.⁹ This testing increased further following publication of national FIT guidelines in July 2022, which was later endorsed by NHS England.¹⁰

All FIT eligible patients were provided with a fecal sample collection device in primary care (OC-Sensor™ sample bottles; Eiken Chemical Company, Tokyo, Japan). Individuals were asked to sample their feces according to instructions, date the sampling device and return in the post to the designated laboratory within 7 days. A pre-paid return envelope was included with the provided FIT kits, alongside instructions on how to sample and return. This returns process ensured direct and timely delivery to the central laboratory, which is within the Department of Immunology and Protein Reference Unit (PRU) at Sheffield Teaching Hospitals, UK.

Returned FIT Samples

The PRU at Sheffield Teaching Hospitals routinely collects data of all FIT samples that it receives. This is used for monitoring as part of the UK NEQAS (National External Quality Assessment Services) scheme for Fecal Hemoglobin. Returned FIT samples are assessed by laboratory technicians and proceed to analysis if adequate FIT specimens are provided. The threshold for analysis is informed by pre-defined technical requirements, which includes provision of sufficient clinical information and considers adherence to test sampling instructions. When inadequate FIT samples are identified and rejected from analysis then the reason for test rejection is documented, and notification made to the referrer that an inadequate test has been provided through local electronic medical record systems.

Measures/Analysis

The primary outcome measure was the monthly rejection rate of FIT samples received by the central laboratory. This was determined by dividing the number of rejected samples by the total number of specimens received. Exploration of the reasons for rejection was conducted to identify common themes.

Statistical analysis was performed using SPSS Statistics, version 25 (IBM Corp), with significance level set at $P < .05$. Categorical variables are summarized using descriptive statistics, including total numbers and percentages, with comparisons between groups performed using the chi-square or Fisher exact test. A Pearson correlation coefficient was computed to assess the linear relationship between FIT returns and rejections.

Ethics and study approval were granted from the UK Health Research Authority (REC reference—22/HRA/3889) and Sheffield Teaching Hospitals (STH22186).

Results

During the 40-month study period, the FIT rejection rate averaged 4.1% (5190 rejections/126422 samples received). Figure 1 highlights the rejection rate breakdown by month, with rejection rates falling dramatically from 17.4% in September 2019 to 1.3% in December 2022 ($P < .001$). Figure 1 also demonstrates how samples received in the laboratory significantly increased following changes to FIT eligibility criteria in March 2021. This increased number of FIT samples returned in the region negatively correlated with FIT test monthly rejection rates ($r = -.780$, $n = 40$, $P \leq .001$).

The most frequent cause for FIT specimens being rejected were for sampling errors (41.4%, 2151/5190). This encompassed test specimens that had inadequate or excess fecal content, incorrect sample containers (eg, non-FIT fecal tests), or due to sample labeling errors. The




Figure 1. FIT samples received and rejected from symptomatic patients.

Table 1. FIT Rejection Causes Delineated by Patient and Non-patient Factors.

	N	%
Total	5190	100
Patient factors		
Sampling error	2151	41.4
No collection date/time	626	12.1
Expired sample submitted	11	0.2
Non-patient factors		
No request form	951	18.3
Combined patient and non-patient factors		
No/incomplete patient information	1367	26.3
Illegible handwriting	37	0.7
Other causes	47	0.9

breakdown of other rejection causes are demonstrated in Table 1. 0.9% (47/5190) of samples were rejected for other causes, which included leaked samples in transit, or when non-FIT investigations (eg, fecal calprotectin) had been requested by the GP. The frequency of these rejection events by month is shared in Figure 2.

Discussion

This is the first study examining FIT rejection rates in symptomatic patients managed within the lower GI diagnostic pathway. Our work demonstrates how FIT rejection rates have fallen significantly over time, with an overall rejection rate of 4.1% seen. This finding influences clinical decision-making in a time-dependent pathway, which may lead to CRC diagnostic delays and potential test abandonment. Rejected tests also significantly influence NHS resource use and costs. This work is pertinent to patients, clinicians, and commissioners of colorectal services. It also provides the foundations for designing future targeted interventions that reduce rejection rates, with both patient and

non-patient factors requiring consideration. Maximizing the success of FIT testing, the efficiency of which is largely unmeasured, is pivotal in providing rapid access to diagnostics to those patients who most require it.

The large cohort and timeframe of review are strengths of this study. The data presented is also derived from English primary care, reflective of unselected real-world experience of FIT in symptomatic individuals. A limitation of this work is that patient-level or GP practice data was not collected. This could have helped determine whether sociodemographic variations were factors in samples being rejected. This has been shown in previous research to influence FIT returns, which may also be pertinent to its accurate completion.¹¹ Patient-level data may have also allowed exploration about whether samples were re-submitted for processing by patients after initial rejection.

Another limitation of this observational study is that uncertainty exists about what improved FIT rejection rates over time. The local Cancer Alliance delivered regular lower GI pathway updates to GP practices, provided educational events and gave patient information leaflets on stool collection (that included diagrams). These could all potentially explain improvements in the FIT rejection rate over the study period. Another plausible explanation is that GP and healthcare professionals became more familiar with FIT usage over time, which positively impacted the rejection rate. The reduction in the “no request form” outcome may reflect changes between 2019/2020, whereby local GPs started requesting FIT electronically, and were encouraged to print electronic labels and place them onto sampling containers at the time of requesting. The study period also covers the COVID-19 pandemic, where rapid and continuous changes to patterns of patient presentation and service delivery occurred in all parts of the NHS.

Previous research has shown that patient satisfaction with symptomatic FIT is high,¹⁷ however a paucity of research exists examining the accurate completion of submitted FIT samples. Two previous studies from the USA showed FIT rejection rates between 17% and 42% in asymptomatic (screening) populations.^{14,15} This high rejection rate may reflect differing national processes for administering FIT. It may also reflect variations in patients’ motivations, with symptomatic individuals more likely to adhere to correct test performance when compared to asymptomatic individuals, having already exhibited health-seeking behavior by consulting with their GP. We have been unable to identify any published studies on FIT rejection rates in symptomatic populations. However, anecdotal experience from colleagues in other Cancer Alliances supports FIT rejection being a prevalent problem within the LGI diagnostic pathway. In London, previous unpublished research suggests FIT rejection rates were estimated to be 9%.¹⁸ This has led to an initiative using a poster within GP practices, aimed at enhancing sampling adherence.




Figure 2. Percentage of FIT samples rejected by cause.

It is recognized from previous studies that diagnostic fecal tests can be challenging for patients, which influences test completion, return, and rejection rates.¹⁹⁻²¹ Embarrassment, concerns around hygiene and contamination, discretion and privacy are all factors, which uniquely influence this method of diagnostic testing.¹⁹ A recent systematic review and meta-analysis of blood specimen rejection rates demonstrated a pooled prevalence of 1.99% (16118499 specimens analyzed).²² This finding is lower than our 4.1% FIT sample rejection rate, supporting differences between fecal and blood sampling for diagnostic purposes. Common to both testing modalities was the identification of missing patient's identification, inappropriate containers, labeling errors, and specimens not meeting predefined technical requirements (pre-analytic issues).²² These pre-analytical phase errors have been identified in previous research to account for 70% of all blood sampling errors seen within the laboratory.^{22,23}

Our study findings have implications to patients, clinicians, and commissioners of colorectal services. The rejection of FIT samples from the laboratory can lead to CRC diagnostic delays, which could adversely impact treatments. Prompt communication to patients and their GPs following test rejection could help to mitigate against these delays. Education within this communication could also increase the likelihood that a repeated sample is provided

and adequate for processing. These findings need to also be considered in the context of non-return of FITs, which although not assessed in this study, has recently been shown to be 9.3% (3631/38920 samples) within a neighboring region.¹¹ Targeted strategies to improve both FIT returns and their accurate completion would help support initiatives to enhance CRC case-detection.

Beyond the diagnostic delays is the consideration of costs. A FIT sample kit is estimated to cost £5.²⁴ NHS England data highlights how 565 534 2-week wait LGI referrals were made in 2022/2023.²⁵ Our previous study demonstrated how FIT performance in primary care was >5 times the number of patients being referred.¹⁶ Using this metric, helps estimate that approximately 2.8 million FIT samples are being performed annually within England. Assuming a 1.5% FIT sample rejection rate would mean that an approximately 42 000 FIT samples are being rejected nationally. This equates to a £210 000 financial loss to the NHS through the submission of inadequate FIT samples. This figure is a conservative estimate as it excludes the cost of laboratory staff time, FIT processing costs, and health-related costs of having diagnostic delays. It also assumes rejection rates are comparable across the country.

These rejected FIT findings are unlikely to be unique to the symptomatic LGI pathway, but also prevalent within the national bowel cancer screening program that utilizes FIT.

Further research is therefore needed to determine rejection rates within other regions and within the asymptomatic population. Finally, our study has identified that both patient and non-patient factors are contributing to FIT sample rejection rates. We suggest that future targeted interventions consider these novel findings within their study design, alongside close engagement with relevant stakeholders.

Rapid diagnostic pathways require efficiency at all stages to ensure earlier and faster diagnosis for patients. This study demonstrates laboratory FIT rejection is common soon after its introduction but reduces over time. This is an under-recognized problem with the lower GI diagnostic pathway and our findings would support targeted interventions to address this important aspect, which could derive significant benefits to both patients and the NHS.

Acknowledgments

The authors wish to thank Simon Tazzyman (Research coordinator, Sheffield Laboratory Medicine), Tracey Turner (South Yorkshire and Bassetlaw Cancer Alliance), and Karen Leivers (South Yorkshire and Bassetlaw Cancer Alliance) for their help and support with the data collection.

Data Availability

The data that supports the findings from this study are available from the corresponding author (MK). This sharing of data would require agreement from the study sponsor (Sheffield Teaching Hospitals) and completion of a data sharing agreement.

Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by funding from the South Yorkshire, Bassetlaw & North Derbyshire Cancer Alliance.

Ethical Approval

Ethics and study approval were granted from the UK Health Research Authority (REC reference—22/HRA/3889) and Sheffield Teaching Hospitals (STH22186).

ORCID iD

Matthew Kurien  <https://orcid.org/0000-0002-4227-9500>

References

1. Cancer Research UK. Bowel Cancer Survival. 2018. Accessed June 7, 2023. <https://www.cancerresearchuk.org/about-cancer/bowel-cancer/survival#:~:text=Survival%20for%20all%20stages%20of%20bowel%20cancer&text=around%2075%20out%20of%20100>
2. Neal RD, Tharmanathan P, France B, et al. Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review. *Br J Cancer*. 2015;112 Suppl 1:S92-S107. doi:10.1038/bjc.2015.48
3. Hamilton W, Walter FM, Rubin G, Neal RD. Improving early diagnosis of symptomatic cancer. *Nat Rev Clin Oncol*. 2016;13(12):740-749. doi:10.1038/nrclinonc.2016.109
4. Sud A, Torr B, Jones ME, et al. Effect of delays in the 2-week-wait cancer referral pathway during the COVID-19 pandemic on cancer survival in the UK: a modelling study. *Lancet Oncol*. 2020;21(8):1035-1044. doi:10.1016/S1470-2045(20)30392-2
5. National Institute for Health and Care Excellence. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care. DG30. NICE. 2017. Accessed July 7, 2023. <https://www.nice.org.uk/guidance/dg30>
6. Domper-Arnal MJ, Hijos-Mallada G, Lanás A. The impact of COVID-19 pandemic in the diagnosis and management of colorectal cancer patients. *Therap Adv Gastroenterol*. 2022;15:17562848221117636. doi:10.1177/17562848221117636
7. Archer T, Aziz I, Kurien M, Knott V, Ball A. Prioritisation of lower gastrointestinal endoscopy during the COVID-19 pandemic: outcomes of a novel triage pathway. *Frontline Gastroenterol*. 2022;13(3):225-230. doi:10.1136/flgastro-2021-101825
8. Arasaradnam RP, Bhala N, Evans C, et al. Faecal immunochemical testing in the COVID-19 era: balancing risk and costs. *Lancet Gastroenterol Hepatol*. 2020;5(8):717-719. doi:10.1016/S2468-1253(20)30185-0
9. National Institute for Health and Care Excellence. Clinical guide for triaging patients with lower gastrointestinal symptoms; 2020. Accessed July 7, 2023. <https://www.nice.org.uk/media/default/about/covid-19/specialty-guides/triaging-patients-with-lower-gi-symptoms.pdf>
10. British Society of Gastroenterology. Joint ACPGIB, BSG and BSGAR considerations for adapting the rapid access colorectal cancer pathway during COVID-19 pandemic. 2022. Accessed July 1, 2023. <https://www.bsg.org.uk/covid-19-advice/covid-19-advice-for-healthcare-professionals/joint-acgbbi-bsg-and-bsgar-considerations-for-adapting-the-rapid-access-colorectal-cancer-pathway-during-covid-19-pandemic/>
11. Bailey JA, Morton AJ, Jones J, et al. Sociodemographic variations in the uptake of faecal immunochemical tests in primary care. *Br J Gen Pract*. 2023;73:e843-e849. doi:10.3399/bjgp.2023.0033
12. Coronado GD, Sanchez J, Petrik A, Kapka T, DeVoe J, Green B. Advantages of wordless instructions on how to complete a fecal immunochemical test: lessons from patient advisory council members of a federally qualified health center. *J Cancer Educ*. 2014;29(1):86-90. doi:10.1007/s13187-013-0551-4
13. Georgiou Delisle T, D'Souza N, Davies B, et al. Faecal immunochemical test for suspected colorectal cancer symptoms: patient survey of usability and acceptability. *BJGP Open*. 2022;6(1):BJGPO.2021.0102. doi:10.3399/BJGPO.2021.0102
14. Coury J, Schneider JL, Rivelli JS, et al. Applying the Plan-Do-Study-Act (PDSA) approach to a large pragmatic

- study involving safety net clinics. *BMC Health Serv Res.* 2017;17(1):411. doi:10.1186/s12913-017-2364-3
15. Cheng C, Ganz DA, Chang ET, Huynh A, De Peralta S. Reducing rejected fecal immunochemical tests received in the laboratory for colorectal cancer screening. *J Healthc Qual.* 2019;41(2):75-82. doi:10.1097/JHQ.0000000000000181
 16. Ball AJ, Aziz I, Parker S, Sargur RB, Aldis J, Kurien M. Fecal immunochemical testing in patients with low-risk symptoms of colorectal cancer: a diagnostic accuracy study. *J Natl Compr Canc Netw.* 2022;20(9):989-996.e1. doi:10.6004/jncn.2022.7037
 17. Gil N, Su H, Kaur K, et al. Patient experience and satisfaction with symptomatic faecal immunochemical testing: an explanatory sequential mixed-methods evaluation. *Br J Gen Pract.* 2023;73(727):e104-e114. doi:10.3399/BJGP.2022.0241
 18. Transformation Partners in Health and Care. Improving the quality of symptomatic FIT for bowel cancer. 2022. Accessed July 1, 2023. <https://www.transformationpartnersinhealthandcare.nhs.uk/improving-the-quality-of-symptomatic-fit-for-bowel-cancer/>
 19. Lecky DM, Hawking MK, McNulty CA, group Es. Patients' perspectives on providing a stool sample to their GP: a qualitative study. *Br J Gen Pract.* 2014;64(628):e684-e693. doi:10.3399/bjgp14X682261
 20. Fan K, Morris AJ, Reller LB. Application of rejection criteria for stool cultures for bacterial enteric pathogens. *J Clin Microbiol.* 1993;31(8):2233-2235. doi:10.1128/jcm.31.8.2233-2235.1993
 21. Syed Soffian SS, Safian N, Nawi AM, Ahmad SB, Chan HK, Abu Hassan MR. Rate and associated factors of refusal to perform immunochemical Faecal Occult Blood Test (iFOBT) among semi-urban communities. *PLoS One.* 2021;16(10):e0258129. doi:10.1371/journal.pone.0258129
 22. Getawa S, Aynalem M, Melku M, Adane T. Blood specimen rejection rate in clinical laboratory: a systematic review and meta-analysis. *Pract Lab Med.* 2023;33:e00303. doi:10.1016/j.plabm.2022.e00303
 23. Guimaraes AC, Wolfart M, Brisolaro ML, Dani C. Causes of rejection of blood samples handled in the clinical laboratory of a University Hospital in Porto Alegre. *Clin Biochem.* 2012;45(1-2):123-126. doi:10.1016/j.clinbiochem.2011.10.009
 24. National Institute for Health and Care Excellence. Resource impact report: quantitative faecal immunochemical tests to assess symptomatic people who are at low risk of colorectal cancer in primary care (DG30). 2017 Accessed July 1, 2023. <https://www.nice.org.uk/guidance/dg30/resources/resource-impact-report-pdf-4540427101>
 25. NHS England. 2022/23 quarterly provider based cancer waiting times statistics. 2023. Accessed September 28, 2023. <https://www.england.nhs.uk/statistics/statistical-work-areas/cancer-waiting-times/quarterly-prov-cwt/2022-23-quarterly-provider-based-cancer-waiting-times-statistics/>